ClinicalTrials.gg
CompletedNCT04131595Updated Aug 20, 2020

Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects

A Phase 1 interventional study of MVA-BN-WEV Dose 1 and MVA-BN-WEV Dose 2 in Equine Encephalitis, sponsored by Bavarian Nordic. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-20.

Sponsored by Bavarian Nordic · Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was Jul 2020, 6 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

To assess safety and tolerability as well as immune responses to the MVA-BN-WEV vaccine in the 3 treatment groups receiving different doses.

02

Conditions studied

  • Equine Encephalitis
03

In context

Lead sponsor

Bavarian Nordic is the lead sponsor of 58 studies on the registry; 2 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 12 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Male and female subjects ≥18 and ≤50 years of age at screening (SCR).
    1. General good health, without medical illness, physical exam findings, or laboratory abnormalities, as determined by the investigator.
    1. Prior to performance of any trial specific procedures, the subject has read, signed and dated an form (ICF), having been advised of the risks and benefits of the trial in a language understood by the subject, and has signed the Health Insurance Portability and Accountability Act authorization form (HIPAA).
    1. (BMI) ≥18.5 and ≤35.
    1. Female subjects of and male subjects who are sexually active with a female partner of childbearing potential must agree to the use of an effective method of from at least 30 days prior to administration of the vaccine to until 30 days after the last vaccination. A woman is considered of childbearing potential unless (defined as ≥12 months without a menstrual period at SCR) or surgically sterilize (bilateral oophorectomy, bilateral tubal ligation, hysterectomy). Acceptable contraception methods are restricted to abstinence (abstinence only acceptable if refraining from heterosexual intercourse during the entire period of 30 days prior to administration of the vaccine until 30 days after the last vaccination), double barrier contraceptives, vasectomy, intrauterine contraceptive devices or licensed hormonal products.
    1. Women of Childbearing Potential (WOCBP) must have a negative serum pregnancy test at SCR.
    1. Negative antibody test (anti-HIV), negative surface antigen (HBsAG) and negative antibody to virus.
    1. Troponin I within normal limits at SCR.

Exclusion criteria

Exclusion Criteria:

    1. Pregnant or breast-feeding women.
    1. Subject has an acute or chronic medical condition that, in the opinion of the investigator, would render the trial procedures unsafe or would interfere with the evaluation of the responses, including but not limited to, neurologic, cardiovascular, respiratory, hepatic, hematologic, rheumatologic, endocrine, gastrointestinal, renal, , or conditions.
    1. Laboratory parameters (such as complete blood count, serum biochemistry including (AST), alanine amino transferase (ALT), alkaline phosphokinase (AP), , or creatinine values), pulse rate and/or blood pressure, or (ECG) outside normal range at SCR and deemed by the investigator.
    1. History of or active autoimmune disease; persons with vitiligo or thyroid disease taking thyroid replacement are not excluded. History of Guillain-Barré syndrome or Reye's syndrome.
    1. Known or suspected impairment of immunologic functions including, but not limited to, clinically significant liver disease, diabetes mellitus type I, moderate to severe kidney impairment. A known immunodeficiency syndrome.
    1. Known or suspected previous smallpox vaccination or vaccination with a poxvirus-based vaccine.
    1. Known or suspected previous alphavirus infections (Eastern Equine Encephalitis Virus (EEEV), Venezuelan Equine Encephalitis Virus (VEEV), Western Equine Encephalitis Virus (WEEV), Chikungunya).
    1. History of other than squamous cell or basal cell skin cancer, unless there has been surgical excision at least 6 months prior to SCR that is considered to have achieved cure. Subjects with history of skin cancer must not be vaccinated at the previous tumor site.
    1. Clinically significant mental disorder not adequately controlled by medical treatment.
    1. Active or recent history of chronic alcohol abuse and/or intravenous and/or nasal drug abuse (within the time period of 6 months before SCR).
    1. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. tris(hydroxymethyl)-amino methane, chicken embryo fibroblast proteins, gentamicin, ciprofloxacin.
    1. Known allergy to eggs.
    1. History of anaphylaxis or severe allergic reaction to any vaccine.
    1. Having received any vaccinations or planned vaccinations with a within 30 days prior to first or after last trial vaccination.
    1. Having received any vaccinations or planned vaccinations with an inactivated vaccine within 14 days prior to first or after last trial vaccination.
    1. Recent blood donation (including , plasma and red blood cells) within 4 weeks prior screening, or planned blood donations during active trial phase (until EAP Visit).
    1. Chronic systemic administration (defined as more than 14 days) of >5 mg prednisone (or equivalent)/day or any other immunemodifying drugs during a period starting 3 months prior to administration of the vaccine and ending at the last visit of the active treatment phase. The use of topical, inhaled, ophthalmic and nasal is allowed.
    1. Post organ transplant subjects whether or not receiving chronic immunosuppressive therapy.
    1. Administration or planned administration of immunoglobulins and/or any blood products during a period starting 3 months prior to administration of the vaccine and ending at the last visit of the active treatment phase. Receipt of packed red blood cells given for an emergent indication in an otherwise healthy person, and not required as ongoing treatment is not exclusionary (for example packed red blood cells emergently given during an elective surgery).
    1. History of coronary heart disease, myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or , uncontrolled high blood pressure, significant arrhythmia with or without corrective/ablative surgery, or any other heart condition under the care of a doctor.
    1. Use of any or non-registered drug or vaccine other than the trial vaccine within 30 days preceding the first dose of the trial vaccine, or planned administration of such a drug during the trial period until the Follow-Up (FU) Visit 6 months after the last vaccination visit.
    1. Clinical trial site personnel involved in this trial.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    MVA-BN-WEV Dose 1

    Subjects in treatment Group 1 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 1 x 107 Inf.U in 0.5 mL.

    Biological: MVA-BN-WEV Dose 1

  • Experimental
    MVA-BN-WEV Dose 2

    Subjects in treatment Group 2 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 1 x 108 Inf.U in 0.5 mL

    Biological: MVA-BN-WEV Dose 2

  • Experimental
    MVA-BN-WEV Dose 3

    Subjects in treatment Group 3 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 2 x 108 Inf.U in 2 x 0.5 mL

    Biological: MVA-BN-WEV Dose 3

Interventions

  • BiologicalMVA-BN-WEV Dose 1

    1 x 10\^7 Inf.U MVA-BN-WEV vaccine

  • BiologicalMVA-BN-WEV Dose 2

    1 x 10\^8 Inf.U MVA-BN-WEV vaccine

  • BiologicalMVA-BN-WEV Dose 3

    2 x 10\^8 Inf.U MVA-BN-WEV vaccine.

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability: Number of subjects reporting any serious adverse events (SAE)

    Number of subjects reporting any serious adverse events (SAE)

    Time frame: within 7 months after vaccinations of subjects

07

Study locations

1 site
  • Johnson County Clin-Trials
    Lenexa, Kansas 66219, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Jul 2020, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2019
First posted
Oct 18, 2019
StartActual
Oct 7, 2019
Primary completionActual
Jul 22, 2020
CompletionActual
Jul 22, 2020
Last update
Aug 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04131595
Lead sponsor
Bavarian Nordic
Collaborators
JPM CBRN Medical
Responsible party
Sponsor
First posted
Oct 18, 2019
Start date
Oct 7, 2019
Primary completion
Jul 22, 2020
Completion
Jul 22, 2020
Last update
Aug 20, 2020

Study contacts

Carlos Fierro, MD
principal investigator · JCCT

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion